Monitoring Response to TKI Therapy, Mutational Analysis, and New Treatment Options in CML
Learning Objectives
At the conclusion of this session, the participant should be able to:
- Integrate into professional practice the key updates of the NCCN Guidelines related to CML
Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
Available Credit
- 1.00 Case Manager
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician
- 1.00 Tumor Registrar